{"filings":[{"id":2216765,"accession_number":"0001193125-26-346817","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2026-08-12T20:05:23+00:00","items":["5.02"],"status":"ready","headline":"Minerva appoints Anthony Aliquo as Chief Accounting Officer; CFO Fred Ahlholm remains","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anthony Aliquo appointed CAO and principal accounting officer effective Aug 10, 2026.","Fred Ahlholm ceases as principal accounting officer but continues as CFO and principal financial officer.","Aliquo's base salary increased to $296,696 effective July 1, 2026; bonus target raised to 35%.","Aliquo previously VP/Controller; CPA with over 10 years experience, ex-BDO and Deloitte."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2115117,"accession_number":"0001193125-26-339147","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2026-08-07T11:13:34+00:00","items":["2.02","9.01"],"status":"ready","headline":"Minerva Q2 GAAP net income $17.5M on $27.6M non-cash warrant gain; adjusted loss $7.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 GAAP net income of $17.5M ($0.36 basic, $(0.14) diluted) vs net loss of $3.3M year-ago; driven by $27.6M non-cash warrant gain.","Adjusted non-GAAP net loss of $7.8M vs $3.0M year-ago; H1 adjusted loss $15.1M vs $6.4M. Cash $75.4M, down from $82.4M at Dec 31, 2025.","R&D expense $7.2M (Q2) vs $1.3M; G&A $3.5M vs $2.1M, up on C19 trial costs, professional fees and compensation.","Phase 3 C19 roluperidone trial (380 patients, ~40 sites) on track; Phase A topline expected 2H 2027, Phase B 2H 2028.","Scientific Advisory Board expanded to 11 members, adding Correll, Leucht and Sand."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":860937,"accession_number":"0001193125-26-257379","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2026-06-04T20:05:19+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"Shareholders approve officer exculpation charter amendment; board adopts updated bylaws at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved exculpation amendment to limit officer liability for monetary damages to full extent under Delaware law.","Shareholders approved elimination of exclusive forum provision from charter.","Board adopted amended bylaws updating advance notice, universal proxy rules, exclusive forum for Securities Act claims.","Elected Dr. David Kupfer and Jan van Heek as directors, each term to 2029.","Ratified Deloitte & Touche as auditor for FY 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":695997,"accession_number":"0001193125-26-241930","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2026-05-27T20:18:04+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Minerva enters $75M ATM offering; Phase 3 roluperidone relapse phase extended to 52 weeks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $75M in common stock may be sold at-the-market through Leerink Partners; 3% commission.","Phase 3 C19 trial relapse assessment phase extended from 40 to 52 weeks after FDA feedback.","Topline efficacy results from C19 trial expected H2 2027; relapse data expected H2 2028.","No obligation to sell any shares; program provides capital-raising flexibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93984,"accession_number":"0001193125-26-205129","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Minerva Q1 GAAP net loss $125.4M on warrant revaluation; Phase 3 roluperidone trial advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated; first patient screened March 2026; topline data expected 2H 2027.","GAAP net loss $125.4M ($2.86/share) vs $3.8M ($0.50) prior year; non-GAAP adjusted net loss $7.3M ($0.17/share).","Cash and equivalents $78.2M at March 31, down from $82.4M at Dec 31; warrant exercise raised net $1.2M in Q1.","Leadership: Appointed Jim O’Connor CBO & General Counsel; President Geoff Race left, remains as consultant.","R&D spend rose to $5.3M from $1.4M on trial costs; G&A $11.4M included $6.6M one-time stock comp charge."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93983,"accession_number":"0001193125-26-143986","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Minerva Neurosciences sets 2026 annual meeting for June 3; proposal deadlines announced","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting of stockholders scheduled for June 3, 2026.","Stockholder proposals for proxy inclusion due by April 16, 2026.","Nominations and other business proposals due by April 21, 2026.","All notices must be sent to Minerva's Burlington, MA office."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93982,"accession_number":"0001193125-26-140148","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Minerva Neurosciences President resigns; James O'Connor named Chief Business Officer and General Counsel","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Geoffrey Race resigned as President effective March 31, 2026 after 16 years with the company.","Race will serve as consultant from April 15, 2026 to April 14, 2027 at £333/hour (min 35 hrs/month).","James O'Connor appointed Chief Business Officer and General Counsel effective April 21, 2026.","Press release highlights focus on roluperidone for negative symptoms of schizophrenia and planned Phase 3 trial.","Race receives full vesting of outstanding stock options with exercise period extended to January 1, 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106006,"accession_number":"0001193125-26-101074","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Minerva (NERV) Q4 non-GAAP adj loss $7.1M; cash $82.4M; Phase 3 roluperidone on track for Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Non-GAAP adjusted net loss for Q4 2025 was $7.1M ($0.64/sh) vs $4.0M ($0.53/sh) in Q4 2024.","GAAP net loss for Q4 2025 was $283.7M ($25.51/sh), driven by $321.5M non-cash preferred stock and warrant issuance expense.","Cash, cash equivalents and restricted cash at Dec 31, 2025: $82.4M, up from $21.5M at Dec 31, 2024, from $80M private placement.","Phase 3 confirmatory trial of roluperidone for negative symptoms of schizophrenia on track for Q2 2026; topline data expected 2H 2027.","R&D expense for Q4 2025 was $2.2M vs $2.0M for Q4 2024, reflecting higher consultant fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106005,"accession_number":"0001193125-26-034538","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Minerva unveils Phase 3 trial design for roluperidone; planned start Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 trial to enroll 380 patients with negative symptoms of schizophrenia; 1:1 randomization to placebo or 64 mg roluperidone.","Primary endpoint: change from baseline in PANSS Marder negative symptoms factor score (NSFS) at 12 weeks.","After 12 weeks, patients enter 40-week relapse assessment phase; crossover to roluperidone or antipsychotics.","Topline efficacy results expected H2 2027; relapse assessment data expected H2 2028.","Trial initiation (first patient screened) subject to FDA feedback, targeted Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122301,"accession_number":"0001193125-25-328715","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Minerva Neurosciences stockholders approve increase in authorized common shares to 250M and 12.5M new equity plan shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved increasing authorized common shares from 125M to 250M. Votes: 4,917,181 for, 314,773 against.","Approved amendment to 2013 Equity Plan adding 12,500,000 shares for issuance under the plan. Votes: 3,653,490 for, 32,045 against.","Elected Fouzia Laghrissi-Thode and Inderjit Kaul as directors with 3,502,340 and 3,650,817 votes for, respectively.","Approved issuance of common shares upon conversion of Series A Preferred Stock. Votes: 2,909,574 for, 114,818 against.","Ratified Deloitte & Touche as independent auditor for FY2025 with 5,152,013 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122300,"accession_number":"0001193125-25-287048","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Minerva Neurosciences appoints Dr. Inderjit Kaul to board; Kaul led Cobenfy schizophrenia program at BMS","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kaul appointed to Minerva's board (Class II) effective Nov 14, 2025; board size increased to 6.","Received initial option grant of 9,500 shares vesting quarterly over 3 years; $40,000 annual cash retainer.","Consulting agreement: $450/hr for 25-30 hrs/month, six-month term; equity top-ups tied to roluperidone milestones.","Kaul previously SVP Late-Stage Clinical Development at BMS, led Cobenfy development for schizophrenia; currently CMO of Draig Therapeutics.","Appointment follows recent $200M private placement to fund confirmatory Phase 3 trial of roluperidone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122299,"accession_number":"0001193125-25-245552","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["1.01","3.02","5.03","7.01","9.01"],"status":"ready","headline":"Minerva Neurosciences raises up to $200M to fund Phase 3 trial of roluperidone","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement: $80M upfront Series A preferred; Tranche A warrants for another $80M (cash exercise), Tranche B warrants for $40M contingent on milestone event.","Proceeds to finance Phase 3 confirmatory trial, NDA resubmission, and U.S. commercial launch readiness for roluperidone in negative symptoms of schizophrenia.","Board to increase by up to three directors designated by Vivo Capital, expected to have schizophrenia trial experience.","Closing expected October 23, 2025; led by Vivo Capital with participation from Janus Henderson, Farallon, and others.","Company notes alignment with FDA on confirmatory trial design announced August 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174928,"accession_number":"0001193125-25-057901","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Minerva Neurosciences regains Nasdaq compliance with net income rule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq Panel confirmed compliance with Listing Rule 5550(b)(3) (minimum $500K net income from continuing operations).","Company subject to a one-year discretionary monitor; any future deficiency triggers automatic delist process.","Prior deficiencies for Market Value of Listed Securities (<$35M) and Equity Rule are now resolved.","Panel closed the matter; listing on Nasdaq Capital Market continues effective March 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174927,"accession_number":"0001193125-25-005042","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq Panel grants Minerva continued listing subject to equity compliance by March 31, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company must file disclosure on transactions to meet $2.5M minimum stockholders' equity by 3/31/25.","Must also provide 12-month income projections with underlying assumptions to Panel by same deadline.","Company is working toward compliance but states no assurance of regaining or maintaining listing.","Original deficiency was market value below $35M; now equity compliance is the key condition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191891,"accession_number":"0001193125-24-271652","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Minerva Neurosciences annual meeting vote results: directors elected, say-on-pay approved, auditor ratified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Hans Peter Hasler elected with 3,384,409 For, 353,053 Withheld; Dr. Remy Luthringer elected with 3,705,617 For, 31,845 Withheld (1,624,748 broker non-votes each).","Advisory vote on executive compensation passed: 3,631,040 For, 101,614 Against, 4,808 Abstain (1,624,748 broker non-votes).","Ratification of Deloitte & Touche as auditor for FY2024 approved: 5,134,745 For, 160,496 Against, 66,969 Abstain (no broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191890,"accession_number":"0001193125-24-236726","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Minerva Neurosciences receives Nasdaq delisting notice for MVLS non-compliance; to request hearing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Second Nasdaq notice for continued non-compliance with $35M minimum Market Value of Listed Securities; delisting determination unless hearing requested.","Company to request Nasdaq Hearings Panel hearing, which will stay suspension/delisting pending outcome.","Panel may grant extension to April 5, 2025; no guarantee of regaining compliance or continued listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208350,"accession_number":"0001193125-24-219590","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Minerva Neurosciences sets 2024 annual meeting for Dec 5, stockholder deadline Oct 1","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for December 5, 2024, more than 30 days from 2023 meeting anniversary.","Stockholder proposals and nominations due by close of business on October 1, 2024.","Deadline applies to both Rule 14a-8 proposals and other business or director nominations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226007,"accession_number":"0001193125-24-150357","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Jeryl Hilleman resigns from Minerva Neurosciences Board; Audit Committee roles reassigned","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeryl Hilleman resigns from Board and Audit Committee Chair, effective August 6, 2024.","Jan van Heek appointed as new Audit Committee Chair; Dr. David Kupfer added to committee.","Resignation not due to any disagreement with the Company, management, or Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226006,"accession_number":"0001193125-24-094620","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2024-04-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Minerva Neurosciences receives Nasdaq delisting notice for low market value","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["MVLS below $35M minimum for 31 consecutive business days as of April 10, 2024.","Grace period of 180 days until October 7, 2024 to regain compliance.","To regain compliance, MVLS must be at least $35M for 10 consecutive business days.","Failure to comply may result in delisting from the Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245096,"accession_number":"0001193125-24-047110","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA issues Complete Response Letter for roluperidone; NDA not approved","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cited single positive study insufficient; requires at least one additional positive well-controlled trial.","CRL also demands data on co-administration with antipsychotics and clinically meaningful change.","Safety database inadequate: too few subjects on 64 mg for 12+ months.","Minerva will request a meeting with FDA to discuss path forward; CEO expresses disappointment.","Roluperidone was targeting negative symptoms of schizophrenia, an unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279728,"accession_number":"0001193125-23-245615","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Minerva Neurosciences stockholders approve all proposals at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors David Kupfer and Jan van Heek elected with ~3.25M and ~3.37M votes, respectively.","Equity plan amendment approved to increase authorized shares by 700,000; 3.28M for, 577K against.","Advisory vote on named executive officer compensation passed with 3.74M for, 71K against.","Ratification of Deloitte & Touche as auditor for FY2023 approved with 5.06M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298168,"accession_number":"0001193125-23-176877","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2023-06-28T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Minerva Neurosciences raises $20M in PIPE at $10/share for roluperidone launch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$20M from 1,425,000 shares at $10/share and 575,575 pre-funded warrants at $9.99.","Investors include Boehringer Ingelheim and Federated Hermes Kaufmann Funds; Boehringer gets board observer rights.","Net proceeds to support U.S. regulatory approval, commercialization, and launch of roluperidone for negative schizophrenia symptoms.","Closing expected on or about June 30, 2023, subject to customary closing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298167,"accession_number":"0001193125-23-169682","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Minerva Neurosciences regains Nasdaq compliance on minimum market value requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq Compliance Notice on June 16, 2023, after MVLS exceeded $35M for 10 consecutive business days.","Previously faced delisting due to non-compliance; hearing before Nasdaq Hearings Panel cancelled.","Company's common stock will continue trading on Nasdaq Capital Market.","Regained compliance resolves listing uncertainty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298166,"accession_number":"0001193125-23-159827","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Minerva Neurosciences receives Nasdaq delisting determination; intends to request hearing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received second Nasdaq notice on May 31 for continued non-compliance with minimum Market Value of Listed Securities ($35M).","Failed to regain compliance by May 30, 2023 deadline; Nasdaq staff determined to delist.","Company intends to request a hearing before Nasdaq Hearings Panel to stay delisting action.","Panel may grant extension up to November 27, 2023; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298165,"accession_number":"0001193125-23-137134","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Minerva Neurosciences director William Doyle resigns; board appoints replacements","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Doyle resigned from the Board effective May 3, 2023, including as Chair of Compensation Committee.","Mr. Doyle's resignation was not due to any disagreement with the Company, management, or Board.","Fouzia Laghrissi-Thode, M.D., appointed Chair of Compensation Committee effective May 3, 2023.","Hans Peter Hasler appointed as a new member of Audit Committee effective May 3, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298164,"accession_number":"0001193125-23-128726","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Minerva Neurosciences announces FDA files NDA for roluperidone after appeal of refuse-to-file","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA filed Minerva's NDA for roluperidone on April 27, 2023, to treat negative symptoms in schizophrenia.","FDA had issued a refuse-to-file letter in October 2022; appeal granted by FDA deciding official.","Issues from the April 2022 Type C meeting will be considered during NDA review.","No approved treatments exist for negative symptoms of schizophrenia; roluperidone aims to address that gap."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336682,"accession_number":"0001193125-22-313129","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2022-12-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA upholds refusal to file Minerva's NDA for roluperidone for schizophrenia negative symptoms","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA confirmed refusal-to-file letter dated Oct 14, 2022 remains in effect after Type A meeting on Nov 30, 2022.","NDA for roluperidone for treatment of negative symptoms in schizophrenia denied filing by FDA.","Company will continue to work with FDA and assess next steps for roluperidone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336681,"accession_number":"0001193125-22-307381","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Minerva Neurosciences amends CEO Luthringer's employment agreement with enhanced severance terms","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Remy Luthringer to receive 12 months base salary continuation upon termination without cause.","Pro-rata annual bonus (assumed at 50% of base salary) + accelerated vesting for awards vesting within 6 months.","Base salary set at $600,096 per year.","Amendment effective December 13, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336680,"accession_number":"0001193125-22-297518","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2022-12-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Minerva Neurosciences receives Nasdaq notice for MVLS non-compliance; has until May 30, 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Minerva on Dec 1, 2022 that MVLS fell below $35M for 30 consecutive business days.","Company has until May 30, 2023 to regain compliance by closing at $35M for ten consecutive business days.","No immediate delisting; stock continues trading on Nasdaq Capital Market under symbol NERV.","If not compliant by May 30, 2023, Nasdaq may delist; company may seek extension or appeal.","Company is evaluating options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336679,"accession_number":"0001193125-22-263403","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2022-10-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Minerva Neurosciences receives FDA refusal to file for roluperidone NDA in schizophrenia negative symptoms","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued Refusal to File letter for NDA of roluperidone for negative symptoms of schizophrenia.","No approved therapies exist in US for negative symptoms of schizophrenia; company disappointed.","Company intends to request a Type A meeting to discuss the refusal to file letter.","Roluperidone is a clinical-stage therapy; NDA submission not accepted by FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354071,"accession_number":"0001193125-22-242001","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2022-09-09T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Minerva Neurosciences transfers stock listing to Nasdaq Capital Market to avoid delisting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Transfer from Nasdaq Global Market to Nasdaq Capital Market effective Sept 12, 2022; ticker NERV unchanged.","Company was not in compliance with minimum $10M net equity requirement previously disclosed on March 8, 2022.","Nasdaq approved transfer under Listing Rule 5810(c)(3)(A); company meets all Capital Market continued listing criteria.","No impact on trading; press release issued Sept 9, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354070,"accession_number":"0001193125-22-226016","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2022-08-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Minerva submits NDA to FDA for roluperidone (64 mg) to treat negative symptoms of schizophrenia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NDA supported by two late-stage studies (MIN-101C03 and MIN-101C07) in patients with moderate to severe negative symptoms.","Study MIN-101C03 met primary endpoint: statistically significant reduction in negative symptoms (p≤0.0036) at 12 weeks.","Study MIN-101C07 marginally missed primary ITT analysis (p≤0.064) but showed significance in mITT (p≤0.044) and on key secondary PSP scale.","Company seeks approval for 64 mg dose; no approved therapies currently exist in the US for negative symptoms of schizophrenia.","Additional data provided following March 2022 Type C meeting with FDA to address impact on antipsychotics, comparability of patients, and statistical evidence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371949,"accession_number":"0001193125-22-176540","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Minerva Neurosciences files for 1-for-8 reverse stock split effective June 17, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse split at June 10, 2022 annual meeting; board set ratio at 1-for-8.","Split effective 5:00 PM ET June 17; common stock begins trading split-adjusted on Nasdaq June 21.","No fractional shares issued; cash paid in lieu. New CUSIP number is 603380 205.","Proportionate adjustments made to all outstanding equity awards and shares reserved under equity plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371948,"accession_number":"0001193125-22-174803","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2022-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Minerva Neurosciences shareholders approve reverse stock split ratio of 1:4 to 1:10","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split authorized by 93.5% of votes cast (25.9M for, 1.7M against).","Three directors elected: Hilleman, Laghrissi-Thode, Luthringer (each with ~16M for).","Advisory say-on-pay approved with 17.4M for, 891K against, 9.3M broker non-votes.","Deloitte & Touche ratified as auditor for FY2022 with 27.1M for, 552K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371947,"accession_number":"0001193125-22-103843","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2022-04-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Minerva Neurosciences hosts roluperidone update webcast; no specific details in 8-K","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company held an investor webcast on April 13, 2022, to discuss updates on roluperidone.","The 8-K filing includes only a cover page and dial-in information for the webcast.","No clinical data, regulatory milestones, or financial guidance were disclosed in the filing.","Investors must access the webcast replay or presentation to learn the actual update content."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371946,"accession_number":"0001193125-22-098270","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2022-04-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA says Phase 3 study for roluperidone remains negative; additional data needed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA stated the Phase 3 study is negative under the Hochberg procedure; both 32 mg and 64 mg doses must be significant.","Excluding a site with data integrity issues gave nominal p=0.044 for 64 mg dose, but FDA still deems study negative.","Division raised concerns about monotherapy use, patient identification, and lack of data on coadministration with antipsychotics.","FDA suggested additional data could address concerns; Minerva may begin data collection in parallel with NDA preparations.","Minerva still believes it has two adequate studies and targets NDA submission in summer 2022; webcast April 13."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390855,"accession_number":"0001193125-22-074127","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2022-03-14T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Minerva Neurosciences receives Nasdaq delisting notice for equity shortfall","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Notice received March 8, 2022: stockholders' equity in 2021 10-K fails Nasdaq Rule 5450(b)(1).","Company has 45 days to submit a plan to regain compliance with the Rule.","If plan accepted, Nasdaq may grant up to 180 days from notice date for evidence of compliance.","If plan rejected or extension denied, Company may appeal to Nasdaq Hearings Panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390854,"accession_number":"0001193125-22-056251","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2022-02-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phase 3 roluperidone results published; primary endpoint missed significance in ITT","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Trial published in Schizophrenia Bulletin for roluperidone to treat negative symptoms in schizophrenia.","Primary endpoint NSFS missed statistical significance in ITT (p≤0.064) but hit in m-ITT (p≤0.044).","Secondary endpoint PSP total score statistically significant for 64 mg vs placebo (ITT p≤0.021).","FDA denied pre-NDA meeting in Nov 2021; Type C meeting scheduled; NDA submission planned H1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390853,"accession_number":"0001193125-22-010710","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2022-01-18T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Minerva Neurosciences receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq letter dated Jan 12, 2022, for closing bid price below $1.00 for 30 consecutive business days.","Company has 180 calendar days (until July 11, 2022) to regain compliance.","Compliance requires closing bid price ≥$1.00 for at least ten consecutive business days.","Common stock continues trading on Nasdaq Global Market under symbol NERV; no immediate delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390852,"accession_number":"0001193125-22-002261","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2022-01-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Minerva Neurosciences presents corporate update at LifeSci Partners event on Jan 5, 2022","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation furnished as Exhibit 99.1 to Form 8-K.","Presentation made virtually at the 11th Annual LifeSci Partners Corporate Access Event on January 5, 2022.","No specific financial or clinical updates disclosed in the filing or exhibit text.","Presentation content not deemed filed or incorporated by reference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408965,"accession_number":"0001193125-21-351399","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2021-12-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Roluperidone phase 3 trial: primary endpoint missed in ITT (p=0.064) but significant in mITT; PSP improved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NSFS (primary) for roluperidone 64mg vs placebo: p≤0.064 (ITT), p≤0.044 (mITT).","PSP total score (key secondary) significantly improved for 64mg vs placebo: p≤0.021 (ITT), p≤0.017 (mITT).","Relapse rate during open-label extension: 6% (64mg) and 9% (32mg) over one year.","Trial enrolled 513 schizophrenia patients with moderate to severe negative symptoms; monotherapy design.","Results presented at ACNP meeting December 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408964,"accession_number":"0001193125-21-317782","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2021-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA denies Minerva's pre-NDA meeting request for roluperidone, recommends Type C meeting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA denied pre-NDA meeting for roluperidone (negative symptoms of schizophrenia); recommends Type C guidance meeting instead.","Minerva plans to request the Type C meeting; still targeting NDA submission in first half of 2022.","No FDA-approved drugs exist in the U.S. for negative symptoms of schizophrenia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408963,"accession_number":"0001193125-21-296143","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2021-10-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Minerva Neurosciences promotes Geoff Race to President, Frederick Ahlholm to CFO; pre-NDA meeting planned","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Geoff Race promoted to President effective Oct 11, 2021; he was EVP, CFO, and CBO.","Frederick Ahlholm promoted to CFO effective Oct 11, 2021; previously SVP and CAO.","Company plans to submit pre-NDA meeting request to FDA for roluperidone; potential NDA in H1 2022.","Ahlholm's base salary increased from $373,890 to $400,000; Race's base salary remains at $442,293."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427884,"accession_number":"0001193125-21-287430","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2021-09-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Minerva's roluperidone bioequivalence study meets all PK objectives; pre-NDA meeting planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study showed bioequivalence in AUC_inf between Phase 2b, Phase 3, and planned commercial formulations.","C_max reduced substantially in reformulated Phase 3 and commercial tablets vs Phase 2b formulation.","Commercial formulation bioequivalent with or without food; 45 of 48 subjects completed study.","Company to request pre-NDA meeting with FDA for roluperidone for negative symptoms of schizophrenia.","No approved treatments in US for negative symptoms of schizophrenia; roluperidone is potential first-in-class."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427883,"accession_number":"0001193125-21-267364","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2021-09-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Minerva Neurosciences appoints Dr. Kuchibhatla as SVP Head of R&D; Dr. Saoud to advisory role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jay Saoud resigns as SVP Head of R&D effective Sept 15, 2021; transitions to consultant through June 2022.","Dr. Ramana Kuchibhatla appointed as Senior VP & Head of R&D effective Sept 16, 2021, reporting to CEO.","Saoud will continue supporting preparation and submission of NDA for roluperidone (negative symptoms of schizophrenia).","Consulting fee: $412.50/hr first 20 hrs/wk, $500/hr beyond; equity awards accelerate upon completion or early termination.","Kuchibhatla has over 35 years drug development experience from PRA Health Sciences, Melior, Targacept, GSK."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}